×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
AFMD – affimed n.v. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
AFMD
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/17
06:30 am
afmd
Affimed Reports Positive Clinical Update on AFM24/Atezolizumab Combination Therapy in Non-Small Cell Lung Cancer (NSCLC)
High
Report
Affimed Reports Positive Clinical Update on AFM24/Atezolizumab Combination Therapy in Non-Small Cell Lung Cancer (NSCLC)
12/12
02:39 pm
afmd
Affimed (NASDAQ: AFMD) had its price target lowered by analysts at Wells Fargo & Company from $20.00 to $15.00. They now have an "overweight" rating on the stock.
Medium
Report
Affimed (NASDAQ: AFMD) had its price target lowered by analysts at Wells Fargo & Company from $20.00 to $15.00. They now have an "overweight" rating on the stock.
12/10
08:00 am
afmd
Affimed (NASDAQ: AFMD) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
Medium
Report
Affimed (NASDAQ: AFMD) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
12/9
01:30 pm
afmd
Affimed Reports Promising Phase 1 Efficacy and Safety Data for AFM28 in Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
Low
Report
Affimed Reports Promising Phase 1 Efficacy and Safety Data for AFM28 in Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
12/9
06:30 am
afmd
Affimed to Host Investor Conference Call Highlighting Clinical Data from AFM24 in Combination with Atezolizumab in Non-Small Cell Lung Cancer
High
Report
Affimed to Host Investor Conference Call Highlighting Clinical Data from AFM24 in Combination with Atezolizumab in Non-Small Cell Lung Cancer
12/8
12:00 pm
afmd
Affimed Announces Positive Results Demonstrating Safety and Efficacy of Acimtamig and AlloNK® Combination in Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL) Patients
Medium
Report
Affimed Announces Positive Results Demonstrating Safety and Efficacy of Acimtamig and AlloNK® Combination in Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL) Patients
12/5
06:30 am
afmd
Affimed Announces Acimtamig and AlloNK® Combination Granted Regenerative Medicine Advanced Therapy (RMAT) Designation by the U.S. Food and Drug Administration (FDA)
Medium
Report
Affimed Announces Acimtamig and AlloNK® Combination Granted Regenerative Medicine Advanced Therapy (RMAT) Designation by the U.S. Food and Drug Administration (FDA)
11/19
09:31 am
afmd
Affimed (NASDAQ: AFMD) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
Medium
Report
Affimed (NASDAQ: AFMD) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
12/17
06:37 am
afmd
Form 6-K Affimed N.V. For: Dec 17
High
Report
Form 6-K Affimed N.V. For: Dec 17
11/14
07:02 am
afmd
Form 6-K Affimed N.V. For: Nov 14
Low
Report
Form 6-K Affimed N.V. For: Nov 14
10/24
02:50 pm
afmd
Form SC 13G Affimed N.V. Filed by: 683 Capital Management, LLC
Low
Report
Form SC 13G Affimed N.V. Filed by: 683 Capital Management, LLC
10/15
06:59 am
afmd
Form 6-K Affimed N.V. For: Oct 15
Low
Report
Form 6-K Affimed N.V. For: Oct 15
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/17
Affimed Announces Appointment of Arndt Schottelius, M.D. Ph.D. as Chief Scientific Officer
27.5%
10/15 Affimed Reports Progress on Key Clinical Development Programs 10.6%
4/14 Affimed NV (NASDAQ: AFMD) had its "outperform" rating re-affirmed by analysts at SVB Leerink LLC. 8.1%
12/17 Affimed Announces Addition to NASDAQ Biotechnology Index 6.9%
8/8 Affimed NV (NASDAQ: AFMD) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 6.1%
6/12 Affimed to Present Data on AFM13 at the 15th International Conference on Malignant Lymphoma in Lugano, Switzerland 4.7%
11/13 Affimed Announces Closing of Public Offering of Common Shares and Exercise of Underwriters’ Option to Purchase Additional Shares 3.9%
11/22 Affimed NV (NASDAQ: AFMD) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "strong sell" rating. 3.3%
4/1 Affimed Announces FDA Granted Orphan Drug Designation for Lead Innate Cell Engager AFM13 for the Treatment of T-cell Lymphoma 3.1%
8/29 Affimed NV (NASDAQ: AFMD) was upgraded by analysts at ValuEngine from a "sell" rating to a "hold" rating. 2.9%
10/15 Affimed Reports Progress on Key Clinical Development Programs 10.6%
4/14 Affimed NV (NASDAQ: AFMD) had its "outperform" rating re-affirmed by analysts at SVB Leerink LLC. 8.1%
12/17 Affimed Announces Addition to NASDAQ Biotechnology Index 6.9%
8/8 Affimed NV (NASDAQ: AFMD) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 6.1%
6/12 Affimed to Present Data on AFM13 at the 15th International Conference on Malignant Lymphoma in Lugano, Switzerland 4.7%
11/13 Affimed Announces Closing of Public Offering of Common Shares and Exercise of Underwriters’ Option to Purchase Additional Shares 3.9%
11/22 Affimed NV (NASDAQ: AFMD) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "strong sell" rating. 3.3%
4/1 Affimed Announces FDA Granted Orphan Drug Designation for Lead Innate Cell Engager AFM13 for the Treatment of T-cell Lymphoma 3.1%
8/29 Affimed NV (NASDAQ: AFMD) was upgraded by analysts at ValuEngine from a "sell" rating to a "hold" rating. 2.9%
TOP News Decliners
11/12
Form 424B5 Affimed N.V.
-13.3%
11/7 Form 6-K Affimed N.V. For: Nov 07 -11.1%
5/22 Q1/2019 3/31/2019 EPS 0.030 ZacksConsensus -0.160 ActVsEst 0.190 - Beat -10.4%
4/28 Form 6-K Affimed N.V. For: Apr 28 -7.1%
8/9 Affimed N.V. (AFMD) Q2 2019 Earnings Call Transcript [The Motley Fool] -6.5%
3/24 Solebury Trout Announces Virtual Conference Series with Presentations from Life Science Companies -5.8%
8/7 Q2/2019 6/30/2019 EPS -0.170 ZacksConsensus -0.160 ActVsEst (0.010) - Miss -4.9%
11/19 Q3/2019 9/30/2019 EPS -0.170 ZacksConsensus -0.140 ActVsEst (0.030) - Miss -4.5%
4/2 Affimed Provides COVID-19-Related Business Update and Announces Full Year 2019 Financial Results Conference Call on April 28, 2020 -3.5%
6/4 Affimed Announces Annual General Meeting of Shareholders -3.3%
11/7 Form 6-K Affimed N.V. For: Nov 07 -11.1%
5/22 Q1/2019 3/31/2019 EPS 0.030 ZacksConsensus -0.160 ActVsEst 0.190 - Beat -10.4%
4/28 Form 6-K Affimed N.V. For: Apr 28 -7.1%
8/9 Affimed N.V. (AFMD) Q2 2019 Earnings Call Transcript [The Motley Fool] -6.5%
3/24 Solebury Trout Announces Virtual Conference Series with Presentations from Life Science Companies -5.8%
8/7 Q2/2019 6/30/2019 EPS -0.170 ZacksConsensus -0.160 ActVsEst (0.010) - Miss -4.9%
11/19 Q3/2019 9/30/2019 EPS -0.170 ZacksConsensus -0.140 ActVsEst (0.030) - Miss -4.5%
4/2 Affimed Provides COVID-19-Related Business Update and Announces Full Year 2019 Financial Results Conference Call on April 28, 2020 -3.5%
6/4 Affimed Announces Annual General Meeting of Shareholders -3.3%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: